Integrated Clinical-Molecular Classification of Colorectal Liver Metastases
-
Published:2023-09-01
Issue:9
Volume:9
Page:1245
-
ISSN:2374-2437
-
Container-title:JAMA Oncology
-
language:en
-
Short-container-title:JAMA Oncol
Author:
Katipally Rohan R.1, Martinez Carlos A.1, Pugh Siân A.2, Bridgewater John A.3, Primrose John N.4, Domingo Enric5, Maughan Timothy S.6, Talamonti Mark S.7, Posner Mitchell C.8, Weichselbaum Ralph R.1, Pitroda Sean P.1,
Affiliation:
1. Department of Radiation and Cellular Oncology, The University of Chicago Medicine, Chicago, Illinois 2. Department of Oncology, Addenbrooke’s Hospital, Cambridge, England, United Kingdom 3. UCL Cancer Institute, University College London, London, England, United Kingdom 4. Department of Surgery, University of Southampton, Southampton, England, United Kingdom 5. Department of Oncology, University of Oxford, Oxford, England, United Kingdom 6. MRC Oxford Institute for Radiation Oncology, Department of Oncology, University of Oxford, Oxford, England, United Kingdom 7. Department of Surgery, NorthShore University HealthSystem, Evanston, Illinois 8. Department of Surgery, The University of Chicago Medicine, Chicago, Illinois
Abstract
ImportancePersonalized treatment approaches for patients with oligometastatic colorectal liver metastases are critically needed. We previously defined 3 biologically distinct molecular subtypes of colorectal liver metastases: (1) canonical, (2) immune, and (3) stromal.ObjectiveTo independently validate these molecular subtypes in the phase 3 New EPOC randomized clinical trial.Design, Setting, and ParticipantsThis retrospective secondary analysis of the phase 3 New EPOC randomized clinical trial included a bi-institutional discovery cohort and multi-institutional validation cohort. The discovery cohort comprised patients who underwent hepatic resection for limited colorectal liver metastases (98% received perioperative chemotherapy) from May 31, 1994, to August 14, 2012. The validation cohort comprised patients who underwent hepatic resection for liver metastases with perioperative chemotherapy (fluorouracil, oxaliplatin, and irinotecan based) with or without cetuximab from February 26, 2007, to November 1, 2012. Data were analyzed from January 18 to December 10, 2021.InterventionsResected metastases underwent RNA sequencing and microRNA (miRNA) profiling in the discovery cohort and messenger RNA and miRNA profiling with microarray in the validation cohort.Main Outcomes and MeasuresA 31-feature (24 messenger RNAs and 7 miRNAs) neural network classifier was trained to predict molecular subtypes in the discovery cohort and applied to the validation cohort. Integrated clinical-molecular risk groups were designated based on molecular subtypes and the clinical risk score. The unique biological phenotype of each molecular subtype was validated using gene set enrichment analyses and immune deconvolution. The primary clinical end points were progression-free survival (PFS) and overall survival (OS).ResultsA total of 240 patients were included (mean [range] age, 63.0 [56.3-68.0] years; 151 [63%] male), with 93 in the discovery cohort and 147 in the validation cohort. In the validation cohort, 73 (50%), 28 (19%), and 46 (31%) patients were classified as having canonical, immune, and stromal metastases, respectively. The biological phenotype of each subtype was concordant with the discovery cohort. The immune subtype (best prognosis) demonstrated 5-year PFS of 43% (95% CI, 25%-60%; hazard ratio [HR], 0.37; 95% CI, 0.20-0.68) and OS of 63% (95% CI, 40%-79%; HR, 0.38; 95% CI, 0.17-0.86), which was statistically significantly higher than the canonical subtype (worst prognosis) at 14% (95% CI, 7%-23%) and 43% (95% CI, 32%-55%), respectively. Adding molecular subtypes to the clinical risk score improved prediction (the Gönen and Heller K for discrimination) from 0.55 (95% CI, 0.49-0.61) to 0.62 (95% CI, 0.57-0.67) for PFS and 0.59 (95% CI, 0.52-0.66) to 0.63 (95% CI, 0.56-0.70) for OS. The low-risk integrated group demonstrated 5-year PFS of 44% (95% CI, 20%-66%; HR, 0.38; 95% CI, 0.19-0.76) and OS of 78% (95% CI, 44%-93%; HR, 0.26; 95% CI, 0.08-0.84), superior to the high-risk group at 16% (95% CI, 10%-24%) and 43% (95% CI, 32%-52%), respectively.Conclusions and RelevanceIn this prognostic study, biologically derived colorectal liver metastasis molecular subtypes and integrated clinical-molecular risk groups were highly prognostic. This novel molecular classification warrants further study as a possible predictive biomarker for personalized systemic treatment for colorectal liver metastases.Trial Registrationisrctn.org Identifier: ISRCTN22944367
Publisher
American Medical Association (AMA)
Subject
Oncology,Cancer Research
Cited by
5 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|